View More Recent Stories

Feb 17, 2017 06:01AM ArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses Primary Endpoint
Feb 17, 2017 06:00AM Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
Feb 8, 2017 07:00AM ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
Dec 5, 2016 07:51AM ArQule (ARQL) Announces Presentation of ARQ 092 Data in SCD at ASH 2016
Dec 5, 2016 06:13AM ArQule (ARQL) Presents ARQ 531 Data at ASH 2016
Dec 4, 2016 09:00PM Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology
Dec 3, 2016 05:45PM Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
Nov 7, 2016 07:00AM ArQule Reports Third Quarter 2016 Financial Results
Nov 3, 2016 09:05AM Advancements in ArQule’s Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology Annual Meeting
Oct 24, 2016 07:00AM ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
Jan 17, 2014 09:34AM Pre-Open Stock Movers 1/17: (NIHD) (ARQL) (TWTR) Higher; (SSNI) (RDEN) (AAWW) Lower (more...)
Jan 16, 2014 06:02PM After Hours Stock Movers 1/16: (ARQL) (SWKS) (TSCO) Higher; (RDEN) (FCEL) (BJRI) Lower (more...)
View More Recent Stories